Roger Pomerantz - 16 Aug 2023 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role: Director
Signature: /s/ Daniel Chevallard, as Attorney-in-Fact
Issuer symbol: VIRX
Transactions as of: 16 Aug 2023
Net transactions value: $0
Form type: 4
Filing time: 18 Aug 2023, 16:51:18 UTC
Previous filing: 09 Jun 2023
Next filing: 29 Aug 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIRX	Stock Option (Right to Buy)	Award	$0	+15,000		$0.000000	15,000	16 Aug 2023	Common Stock	15,000	$1.23	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/12th of the shares subject to the option shall vest each month following the Vesting Commencement Date (as defined below), or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. The Vesting Commencement Date is June 9, 2023.

Content

1/12th of the shares subject to the option shall vest each month following the Vesting Commencement Date (as defined below), or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. The Vesting Commencement Date is June 9, 2023.